Pharmaceutical companies can continue to charge the federal government—and Medicare beneficiaries—full price for a handful of drugs that might have seen price reductions as soon as next year.
That’s because Congress changed the law to outright exempt or delay consideration of more than 300 medications for the Medicare Drug Price Negotiation Program.
That includes 17 of the top 50 products on Medicare’s drug spending list.
Here’s what lawmakers did, why they did it, and how it affects federal and consumer costs.
Medicare Now Negotiates Some Drug Prices
The federal government, the world’s largest purchaser of prescription drugs, has been legally authorized to negotiate prescription drug prices since 2022….
These Drug Prices Won’t Soon Go Down—Here’s Why
